Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.

Vaccine. 2012 Feb 27;30(10):1813-22. doi: 10.1016/j.vaccine.2012.01.001. Epub 2012 Jan 10.

PMID:
22240341
2.

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.

Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.

Vaccine. 2011 Nov 8;29(48):8929-36. doi: 10.1016/j.vaccine.2011.09.055. Epub 2011 Sep 22.

PMID:
21945961
3.

How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.

Coupé VM, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.

Vaccine. 2009 Aug 13;27(37):5111-9. doi: 10.1016/j.vaccine.2009.06.043. Epub 2009 Jun 28.

PMID:
19567242
4.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

5.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

PMID:
19571256
6.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

7.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
9.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338
10.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
11.

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.

Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.

12.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

13.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
14.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
15.

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M.

Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098. Epub 2008 Aug 22.

PMID:
18723068
16.

Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women.

Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N.

Int J Gynecol Cancer. 2010 Apr;20(3):385-92. doi: 10.1111/IGC.0b013e3181d189b8.

PMID:
20375802
17.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
18.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
19.

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.

Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.

Int J Cancer. 2009 Feb 15;124(4):970-8. doi: 10.1002/ijc.24000.

20.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

Supplemental Content

Support Center